Ottobock SE & Co. KGaA has appointed Dr. Katarzyna Mazur-Hofsaess to its Management Board effective 22 June 2026. She succeeds Stefan Heidenreich, whose regular five-year term has ended. Dr. Mazur-Hofsaess brings extensive international experience in medical technology and healthcare, having served on the Management Board of Fresenius Medical Care and as CEO of its Care Enablement segment from 2018 to 2025, and previously leading the EMEA region at Zimmer Biomet. A physician by training, she earned her doctorate at the Medical University of Gdansk and also completed management studies at the Warsaw School of Economics and the University of Minnesota. Ottobock thanked Stefan Heidenreich for his role as Deputy Chairman in shaping the company's strategic development into a listed entity.
Ottobock SE & Co. KGaAAppointment of a new management board member; strategic development into a listed entity mentioned, but no clear positive or negative impact.
Fresenius Medical Care AG & Co. KGaA
Zimmer Biomet Holdings Inc